An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old	DNA Virus Infections, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Infections, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Viral, Skin and Connective Tissue Diseases, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, anogenital human papillomavirus infection, cervix disorder, common wart, female reproductive system disorder, female reproductive system neoplasm, human papilloma virus infection, infectious disease, neoplasm, sexually transmitted disease, skin disorder, skin disorder caused by infection, uterine disorder, viral infectious disease, viral sexually transmitted disease	Active, not recruiting	Phase 3	2025-07-22		NCT05056402

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	3
Xiamen Innovax Biotech Co., Ltd	8
Xiamen University	16

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sichuan Provincial Centre for Disease Control and Prevention	Chengdu	China	2